AYAlexander W. Ying

Alexander W. Ying

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alexander W. Ying has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pre-Exposure Prophylaxis Adherence and HIV Self-Testing App Among Women in the South Bronx: 12-Month Usability, Acceptability, and Feasibility Study

    by Connor G Wright, Terry L Chern, Tara F Abularrage, Julie Franks, Ann Kahn, Shakir Edwards, Harshit H Chellani, Rashaunna Redd, Alexander W Ying, Siddarth Arumugam, et al.

    Background: HIV pre-exposure prophylaxis (PrEP) is underused by cis- and transgender women despite a significant HIV burden. Smartphone technologies are promising tools to support HIV prevention but have yet to be assessed in women. Objective: We conducted a 12-month feasibility study to assess the use and acceptability of a mobile phone app, SmartPrEP, designed to support PrEP adherence and HIV self- and partner-testing among women living in an area of elevated HIV burden in New York City. Methods: Nonpregnant adult cisgender and transgender women who met US PrEP eligibility criteria and were PrEP naïve, reported PrEP use for 4 HIV risk behaviors in the past 6 months, with 58% (23/40) reporting anal or vaginal sex with more than 1 partner. Over the course of the study, although 8 participants withdrew early, and 14 were lost to follow-up, there were 2 pregnancies and 1 HIV seroconversion. PrEP adherence was low, with 80% (32/40) recording 3 doses per week compared to 20% (8/40). In total, 4 participants conducted HIV self- or partner-testing using SmartPrEP during study follow-up. App acceptability assessed at month 12 was moderate to high (median score 3.71 of max 5, IQR 3.47‐4.16). Conclusions: Despite consistently rating the app as acceptable and receiving quarterly HIV testing and counseling, most participants did not achieve optimal PrEP adherence, demonstrating the limitations of this mobile health app among women at elevated risk of HIV. Active navigation and strategies to address gaps in risk perception among women will remain critical, as new, long-acting formulations of PrEP become available.

  • Top Cited Papers

    A SWI/SNF-specific Ig-like domain, SWIFT, is a transcription factor binding platform

    by Siddhant U. Jain, Kaylyn E. Williamson, Alexander W. Ying, Aasha M. Turner, Ruidong Jerry Jiang, Shaunak Raval, Kevin So, Maxwell J. Allison, Akshay Sankar, Daniel D. Sáme Guerra, et al.

    Mammalian switch/sucrose nonfermenting (mSWI/SNF) chromatin remodeling complexes modulate DNA accessibility and gene expression; however, their genomic targeting mechanisms remain incompletely understood. Here, we identify SWIFT [SWI/SNF immunoglobulin fold (Ig-fold) for transcription factor interactions], a conserved transcription factor (TF) binding domain on the SMARCD subunits. SWIFT is necessary and sufficient for direct engagement with the transactivation domain of the PU.1 TF. A single amino acid mutation disrupts PU.1-mSWI/SNF binding, impairs complex targeting, and attenuates oncogenic transcription and proliferation in PU.1-dependent human cancer cells. Dominant expression of the SWIFT domain in isolation sequesters TFs from mSWI/SNF and poisons TF-“addicted” cancer cells. Finally, TFs across diverse families interact with SMARCD paralog-specific SWIFT domains. These results define a major mechanism of cell type– and disease-specific mSWI/SNF chromatin targeting and inform approaches toward therapeutic modulation.


  • Open Access

    mSWI/SNF complex inhibition sensitizes KRAS-mutant lung cancers to targeted therapies via epithelial-mesenchymal subversion

    by Claudia Gentile, William W. Feng, Sean M. Lenahan, Alexander W. Ying, Daren C. Card, Florence T.H. Wu, Nhu-An Pham, Nikolina Radulovich, Pinjiang Mary Cao, Katrina Hueniken, et al.

    Targeted therapies for KRAS -mutant non-small lung cancer (NSCLC) have shown promising clinical results, however, incomplete tumoral responses and the inevitable emergence of therapeutic resistance remain critical challenges. Here we identify mSWI/SNF chromatin remodeling complexes as critical determinants of (EMT)-mediated KRAS inhibitor inefficacy and resistance in KRAS G12C lung cancers. Treatment with the clinical-grade SMARCA4/2 inhibitor, FHD-286, dampens EMT-mediated acquired resistance in drug-responsive models and similarly resensitizes drug-refractory models by rewiring mSWI/SNF chromatin localization and activities that modulate epithelial transcriptional programs and cell state. Further, synergistic mSWI/SNF and KRAS inhibitor combination treatment sensitizes non-G12C KRAS-mutant NSCLC cells to pan-RAS and G12D-specific inhibitors. Finally, FHD-286 and sotorasib combination treatment results in potent anti-tumor efficacy in both G12Ci-resistant and - sensitive organoid models and in vivo patient-derived xenograft (PDX) systems. These data nominate mSWI/SNF inhibition as a combination strategy to improve KRAS inhibitor efficacy, response duration, and to mitigate emergence of resistance.

  • Open Access

    Shifted assembly and function of mSWI/SNF family subcomplexes underlie targetable dependencies in dedifferentiated endometrial carcinomas

    by Jessica D. St. Laurent, Grace D. Xu, Alexander W. Ying, Bengul Gokbayrak, Ajinkya Patil, Joao A. Paulo, Kasey S. Cervantes, Shary Chen, William W. Feng, Akshay Sankar, et al.

    The mammalian SWI/SNF (mSWI/SNF) family of chromatin remodelers govern cell type-specific chromatin accessibility and gene expression and assemble as three distinct complexes: canonical BAF (cBAF), Polybromo-associated BAF (PBAF), and non-canonical BAF (ncBAF). ARID1A and ARID1B are paralog subunits that specifically nucleate the assembly of cBAF complexes and are frequently co-mutated in highly aggressive dedifferentiated/undifferentiated endometrial carcinomas (DDEC/UECs). Here, in cellular models and primary human tumors, we find that ARID1A/B deficiency-mediated cBAF loss results in increased ncBAF and PBAF biochemical abundance and chromatin-level functions to maintain the DDEC oncogenic state. Further, treatment with clinical-grade SMARCA4/2 ATPase inhibitors markedly attenuates DDEC cell proliferation and tumor growth in vivo and synergizes with carboplatin-based chemotherapy to extend survival. These findings reveal the oncogenic contributions of shifted mSWI/SNF family complex stoichiometry and resulting gene regulatory dysregulation and suggest therapeutic utility of mSWI/SNF small molecule inhibitors in DDEC/UEC and other cBAF-disrupted cancer types.